Role of SGLT2 Inhibitors in Type 2 Diabetes With Chronic Kidney Disease

A leading expert provides an overview of the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes.
Jennifer B. Green, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 2.91 MB
Released: July 12, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by independent educational grants from
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company
Bayer HealthCare Pharmaceuticals Inc.

Related Content

Experts provide insight on best practices for management of type 2 diabetes and obesity including those in underserved populations. From Clinical Care Options (CCO)

Released: September 23, 2022

Concise microlearning module featuring expert insight on the appropriate medical management of T2D and CKD from Clinical Care Options (CCO)

Vivian A. Fonseca, MD, FRCP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: September 21, 2022 Expired: September 20, 2023

Unlocked downloadable slides featuring expert insight on the appropriate medical management of T2D and CKD from Clinical Care Options (CCO)

Released: September 21, 2022

Experts provide insight on best practices for management of type 2 diabetes and obesity including those in underserved populations. From Clinical Care Options (CCO)

Released: September 20, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings